Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Fluocinolone Acetonide 0.025% Cream 1X60 Gm Mfg.by:G & W Laboratories Inc, USA

Image 0 of Fluocinolone Acetonide 0.025% Cream 1X60 Gm Mfg.by:G & W Laboratories Inc, USA

Fluocinolone Acetonide 0.025% Cream 1X60 Gm Mfg.by:G & W Laboratories Inc, USA

Call for Price

Fluocinolone Acetonide 0.025 1X60 GM Cream Rx Required Mfg.by:G & W Labs USA. Rx Required. Item no.:RXD2122588 NDC No.:00713-0222-60 UPC No.:307130222600 MPN:022260
Compare to:Synalar? Ingredients:Fluocinolone Acetonide

Have a question?

  Call for Price

Compares to Synalar?

SYNALAR
(fluocinolone acetonide) Cream

Drug Description
SYNALAR (fluocinolone acetonide) Cream 0.025% is intended for topical administration. The active component is the corticosteroid fluocinolone acetonide, which has the chemical name pregna-1,4-diene-3,20-dione,6,9-difluoro-n,21-dihydroxy-16,17-[(1-methylethylidene)bis (oxy)]-,(6α,11β,16α)-.

SYNALAR Cream contains fluocinolone acetonide 0.25 mg/g in a water-washable aqueous base of butylated hydroxytoluene, cetyl alcohol, citric acid, edetate disodium, methylparaben and propylparaben (preservatives), mineral oil, polyoxyl 20 cetostearyl ether, propylene glycol, simethicone, stearyl alcohol, water (purified) and white wax.

INDICATIONS

SYNALAR Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses.
DOSAGE AND ADMINISTRATION

SYNALAR Cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation.

If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

SIDE EFFECTS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

Burning Hypertrichosis Maceration of the skin
Itching Acneiform eruptions Secondary infection
Irritation Hypopigmentation Skin atrophy
Dryness Perioral dermatitis Striae
Folliculitis Allergic contact dermatitis Miliaria